ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the proportion of chronic kidney disease (CKD)
subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of
vitamin D alone who are able to achieve the National Kidney Foundation-Kidney Disease
Outcomes Quality Initiative (NKF-K/DOQI) secondary hyperparathyroidism (HPT) treatment
targets for both biointact parathyroid hormone (biPTH) and calcium-phosphorus (Ca x P)
product.
Phase:
Phase 4
Details
Lead Sponsor:
Amgen
Treatments:
1 alpha-hydroxyergocalciferol Cinacalcet Cinacalcet Hydrochloride Ergocalciferols Vitamin D Vitamins